ArticleMetabolites2026
EHMN 2026: A Thermodynamically Refined, SBML-Standardised Human Metabolic Network for Genome-Scale Analysis and QSP Integration.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EHMN2026Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenome-scale metabolic models (GEMs) are foundational tools for systems biology, enabling quantitative interrogation of human metabolism across physiological and pathological states. However, many legacy reconstructions exhibit heterogeneous identifier usage, incomplete pathway integration, and limited thermodynamic refinement, constraining reproducibility, interoperability, and translational applicability.
methodsWe present EHMN 2026, an update of the Edinburgh Human Metabolic Network. The reconstruction was refined through systematic identifier reconciliation using MetaNetX and ChEBI mappings, duplicate reaction consolidation, thermodynamic directionality assessment, and structured pathway annotation via Reactome. The final model was encoded in Systems Biology Markup Language (SBML) Level 3 Version 2 with the Flux Balance Constraints (FBC2) package, ensuring explicit gene-protein-reaction (GPR) representation and compatibility with modern constraint-based modelling toolchains.
resultsEHMN 2026 comprises 11 compartments, 14,321 metabolites (species), and 22,642 reactions, supported by 3996 gene products. Of all reactions, 9638 (42.6%) contain GPR associations, linking metabolic transformations to 2887 unique Ensembl gene identifiers (ENSG). Pathway integration yielded 2194 unique Reactome identifiers, providing structured pathway-level organisation of metabolic functions. Thermodynamic refinement reduced infeasible energy-generating cycles and improved reaction directionality coherence while preserving global network connectivity. The reconstruction is fully SBML-compliant and portable across major modelling platforms. Compared with Recon3D and Human1, EHMN 2026 uniquely combines native Reactome reaction-level annotation, systematic MetaNetX identifier harmonisation, documented thermodynamic cycle elimination (37 cycles, 0 remaining), and an 11-compartment architecture supporting organelle-specific modelling-features designed for QSP and multi-layer integration applications.
conclusionsEHMN 2026 delivers a rigorously harmonised, thermodynamically refined, and pathway-annotated human metabolic reconstruction with enhanced annotation depth and standards-based interoperability. By combining genome-scale coverage with structured gene and pathway integration, the model establishes a robust computational backbone for reproducible metabolic analysis and provides a scalable foundation for future multi-layer systems pharmacology and integrative modelling frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.